BIOTECH
We are engineering breakthrough nucleoside building blocks to create smarter RNA therapies
Our Story
Cloudburst is a seed-stage platform company actively developing an expanding library of structurally tailored nucleoside analogs to rapidly fine tune RNA medicines that target disease at its genetic roots.
​
Our journey started with a simple but powerful idea: chemistry can solve enduring problems that have long eluded medicine. As chemists and industry veterans backed by decades of cross-disciplinary expertise, we saw enormous untapped potential in nucleosides, a field brimming with opportunity but limited to using old tools. We knew we could do better.
​
At Cloudburst, we are applying the concept of chemical space, the vast range of possible molecular structures, to oligonucleotide therapeutics. Viewing them as large small molecules allows us to unlock transformative possibilities, paving the way for next-generation therapies that redefine care and drive personalized medicine forward.
Our Team
We are leading experts in nucleoside chemistry
At Cloudburst, we bring over 40 years of combined expertise in medicinal chemistry, process development, and biology. Our world-renowned multidisciplinary team blends visionary thinking with scientific rigor and entrepreneurial agility, enabling us to navigate complexity and deliver impactful solutions.
​
We cultivate a collaborative, inclusive culture that recognizes diverse perspectives as the lifeblood of scientific breakthroughs.
​
Rooted in beautiful British Columbia, Canada, we draw energy and inspiration from the natural landscapes that surround us to rethink what’s possible.
Experienced leadership
Dr. Rob Britton, Co-Founder and CEO
Dr. Rob Britton, an accomplished chemist with over 25 years in organic, medicinal, and process chemistry, leads Cloudburst Biotech’s strategic vision and technical innovation. After earning his PhD at the University of British Columbia, Rob completed postdoctoral research as an NSERC Fellow at the University of Cambridge. He held a senior role in Process Research at Merck Frosst Canada before joining the faculty at Simon Fraser University, where he now serves as Full Professor. Rob’s entrepreneurial success as founder of Carbaform and his leadership at Cloudburst underscore his commitment to advancing next-generation therapeutics.
Dr. Matt Nodwell, Co-Founder and CSO
Dr. Matt Nodwell, a seasoned expert in chemistry and biology, has over 20 years of experience spanning academia and industry. A native of British Columbia, Matt completed his PhD at the University of British Columbia and pursued advanced research as a Humboldt Fellow at the Technical University of Munich. As Cloudburst's Chief Scientific Officer, he drives the company’s R&D initiatives, leveraging his multidisciplinary expertise to advance novel therapeutic solutions.
Our Values
INNOVATION
We are relentless.
We forge new paths that go beyond incremental advances to create life-changing medicines.
INCLUSIVITY
Our strength is our team.
We cultivate a supportive, empowering culture that values diverse perspectives and drives impactful science.
EXCELLENCE
Every detail counts.
We uphold strict standards of scientific rigor and intellectual honesty in our endeavors.
EXPLORATION
Curiosity drives us.
We embrace uncertainty as a catalyst for growth and take calculated risks to build resilience and drive progress.
SUSTAINABILITY
We do more with less.
We prioritize development of green and scalable practices, always mindful of the broader impact of our choices.
PRAGMATISM
We are grounded.
We anchor our decisions on tangible solutions that connect deeply to the lives we aim to improve.